Announcement on Result of Shareholding Reduction by Shareholder
Filed with SSE · · 4 pages · Chinese
Bio-Thera Solutions, Ltd. on 6ix
Earlier from Bio-Thera Solutions
- Announcement on Return of Idle Raised Funds Temporarily Used to Supplement Current Capital
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT1308 Injection Combined with BAT4706 Injection and BAT8008 for Injection for Treatment of Advanced Solid Tumors
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (BAT5906)
- Announcement on the Change of Office Address and Contact Information of Investors
- Announcement on Voluntary Disclosure of Semi-annual Earnings Preannouncement for 2025
Later from Bio-Thera Solutions
- Announcement on Using Partial Idle Raised Funds to Temporarily Supplement Current Capital
- Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
- The European Commission (EC) Approves Bio-Thera Solutions' BAT2206 (USYMRO®, ustekinumab), a biosimilar referencing Stelara®
- Notice on Convening the 2nd Extraordinary General Meeting in 2025
- Announcement on Convening the Semi-annual Collective Performance Briefing for Innovative Drug Industry on SSE STAR Market 2025
Follow Bio-Thera Solutions into a list and get an email when it puts out news.
Follow Bio-Thera Solutions